Member Info for Pingu777

Agreed gheko

He may have had the money in 2018 but clearly it was no where near ready. Have to have manufacturability ticked off. CDX final molecule wasn’t agreed until months ago and HEMO CAR T wasn’t even a thing back then.

An IND app May happen pretty soon though all things being well. Studies must be near conclusion.

Quest, If the drugs (any of them) are successful then they’ll replace chemo for blood cancer. If the MCap is still £80m at that point I’d eat my hat.

Lots of talk of hope from people who don’t read up and don’t have any intention of being here for another 2yrs or so until proof of concept is demonstrated at the end of pages 1/2a trials.

Remember, HEMO, has six products on its portfolio currently.

Patience will be very helpful for you. The recovery may start sooner than we think (and many cast doubt upon)

Totally agree in entirety mjng, recommended.

GlobalCo haven’t pulled out Micky. They just didn’t buy it at its current stage of development.

We haven’t heard how CDX will move forward, with or without GlobalCo, yet. I remain confident GlobalCo will have to stay involved for CDX to get to clinical trials.

But I know nothing!! So I’d ignore me.

Perky start!

A further bit of news would be pleasant. Something like a Monday 7am RNS and a bit hype this aft would be nice.

Sorry. Understood. Filtered a few so I’ll stop responding now.

My mum always used to say “beware of derampers masquerading as a voice of reason, son!”

She was pretty smart.

Tremendously boring!!

You talk needing progress updates before you’ll invest more. We’ve literally just had them for all products. Then you say you’re not expecting anything but your not happy with the current position. I’m getting a strong scent of BS as you muddle up your stories.

The bottom line is you’re continually negative and thankfully everyone knows.

I don’t block anyone. But you will be ignored from now for me. Adios.

You don’t want to know more, you just spout negativity.

What exactly are you looking for in terms of an update? Just a month ago the Year End report provided up to date info on all products in the portfolio!

A month later you expect what pray tell?

The issues around confidentiality will always remain so he’s not going to run us through the details of his discoveries. He’s told us what their targets are and it involves getting to IND apps hopefully this year. In the meantime what else do you expect to hear?

Glad your investment portfolio is going well. Good luck.

Hahahaha SSCCSS, you’re good value that’s for sure.

It lists in the RNS it is applicable to multiple treatment types that have the target protein. So it is broad in the sense that it covers multiple illnesses with the same targets proteins. You just need to read it properly!

You didn’t get your top up in did you?

Let’s talk about the RNS:

“The Company continues to progress the laboratory and commercial development of the CDX antibody, and is focused on bringing it to clinical trials.“

SSCCSS everyone knows your agenda. You wanted in cheaper and said we’d drop to 1.5p.

There is £10m more cash in the bank also SSCCSS. You seem to miss this bit in your market cap considerations.

Plenty of graft being put in today. Money talks.

Barbershop
Your deliberate misunderstandings are tiring to even read.
Buy. Hold. Wait.

Surely we’re nearly completely done now?! The odd decent sells into small rises have reduced to the odd one now.

This means there is a solid floor to the price. Anyone wanting out has exited the building. Even traders want to hold to mid 2s minimum with longer term holders knowing HEMOs potential can make a mockery of this market cap over the remainder rod this year and beyond.

The smart money has to be piling in soon in my view. The value and down side risk profile of HEMO has never been so good!

Vlad, let us know the good stuff please (Confidentiality agreements allowing).

-CDX and GlobalCo
-Lupus our own candidate and partners Eli and J&J
-CAR T with PENN... do they like it?
-CBR... one candidate progressing or two?
- the mice... have to wait til clinical trials whether projected results replicate from the mice preclinical to the humans. But I reckon it’ll all be worth the wait from everything I’ve read.

Revisit the year end report (30/4/2021 RNS) if you want a refresher on HEMOs progress and product portfolio!

Stuff to do, life to live dickie! What’s up?

Time is on our side.

*doesn’t suit